Načítá se...
Details of risk–benefit communication in informed consent documents for phase I/II trials
BACKGROUND: Informed consent documents for clinical studies should disclose all reasonably foreseeable risks and benefits. Little guidance exists on how to navigate the complexities of risk–benefit communication, especially in early clinical research. Practice-oriented development of such guidance s...
Uloženo v:
| Vydáno v: | Clin Trials |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7876653/ https://ncbi.nlm.nih.gov/pubmed/33231107 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1740774520971770 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|